Introduction:Basic information about Memogain CAS 224169-27-1, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Memogain Basic information
| Product Name: | Memogain |
| Synonyms: | Memogain;GLN-1062;6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, 6-benzoate, (4aS,6R,8aS)-;Galantamine benzoate D6Q: What is Galantamine benzoate D6 Q: What is the CAS Number of Galantamine benzoate D6;Galantamine benzoateQ: What is Galantamine benzoate Q: What is the CAS Number of Galantamine benzoate Q: What is the storage condition of Galantamine benzoate;Inhibitor,GLN-1062,GLN 1062,inhibit,GLN1062;(4aS,6R,8aS)-3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-yl benzoate;GLN-1062, 10 mM in DMSO |
| CAS: | 224169-27-1 |
| MF: | C24H25NO4 |
| MW: | 391.46 |
| EINECS: | |
| Product Categories: | |
| Mol File: | 224169-27-1.mol |
|
Memogain Chemical Properties
| Boiling point | 523.2±50.0 °C(Predicted) |
| density | 1.28±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | Soluble in DMSO |
| pka | 7.78±0.40(Predicted) |
| form | Solid |
| color | White to yellow |
| InChI | InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1 |
| InChIKey | JKVNJTYHRABHIY-WXVUKLJWSA-N |
| SMILES | N1(C)CC2=CC=C(OC)C3O[C@]4([H])[C@@](C=C[C@H](OC(=O)C5=CC=CC=C5)C4)(C2=3)CC1 |
Safety Information
Memogain Usage And Synthesis
| Uses | Galantamine Benzoate-D3 is an isotopic labelled compound of Galantamine Benzoate, a pro-drug that slows down plaque deposition and ameliorates behavior in 5X familial Alzheimer's disease mice. |
| in vivo | Benzgalantamine (Memogain, 0.3-3 mg/kg, intranasal, twice a day for 2 weeks) improves cognitive function by promoting neurogenesis in the hippocampus, specifically in the dentate gyrus and CA1 regions of the hippocampus in rats models[2].| Animal Model: | Sprague Dawley rats models[2] | | Dosage: | 0.3-3 mg/kg | | Administration: | intranasal, twice a day for 2 weeks | | Result: | Increased the number of newly generated cells and immunolabeling of synaptic markers in the dentate gyrus and CA1 regions of the hippocampus. |
|
Memogain Preparation Products And Raw materials